Evidence synthesis: The economic evidence was grouped and assessed by type of product distributed and health risk addressed. A total of 15 evaluation studies were included in the economic review, involving campaigns promoting the use of child car seats or booster seats, pedometers, condoms, recreational safety helmets, and nicotine replacement therapy.
Evaluations of effectiveness of media campaigns in public health have increased both in quantity and quality since the 2000s, but with no commensurate improvement in economic evaluations. 3 
Evidence Acquisition
General methods of systematic economic reviews followed by The Community Guide are available online at www.thecommunity guide.org/about/economics.html. Briefly, a primary objective of a Community Guide economic review is to assess the economic value of an intervention, determined from cost-benefit or costutility (cost per quality-adjusted life-year [QALY]) estimates. Separate estimates are also derived for the cost of implementing and sustaining the intervention and the economic benefits from expected healthcare cost and productivity loss averted through reduced morbidity and mortality. Methods specific to the present review are detailed below.
The intervention definition and study inclusion criteria for this economic review are described in the effectiveness review. 2 Briefly, this multicomponent intervention is conceptualized as a health communication campaign that increases awareness of and demand for a health-related product along with free or discounted distribution of that product. The campaign must use at least one mass media channel; the health-related product must be tangible and have been shown to improve health; and the product should not require the services of health professionals for prescription or administration. Studies included in the effectiveness review evaluated the promotion and distribution of six health-related products: child car seats or booster seats, pedometers, condoms, recreational safety helmets, over-the-counter nicotine replacement therapy (NRT), and sun-protection products.
Studies were included in this economic review if they met the intervention definition and provided estimates for one or more of the following: intervention cost, healthcare cost changes, change in productivity at worksites, and change in morbidity and mortality measured in disability-or quality-adjusted life-years. Intervention cost measures the monetary value of resources needed to implement and maintain the intervention, composed of the media promotion and product distribution components. The media promotion and product distribution components are separable activities that may be funded at different levels, and studies that provide comparative economic outcomes for different combinations of the two components were included in this economic review.
Healthcare cost is the sum of costs related to inpatient and outpatient care, drugs, devices, and emergency room visits. Productivity at the worksite is the individual's contribution to value of production, generally measured in terms of wage and salary of the individual. The intervention produces economic benefit when healthcare cost is averted or worksite productivity improves. Studies that provide cost-benefit and cost-utility estimates are central to The Community Guide systematic economic review methods; cost-benefit studies provide monetized values of both cost and benefit of the intervention, and cost-utility studies provide the cost per QALY saved because of the intervention.
This economic review also included studies that provided costeffectiveness based on proximal outcomes that are meaningful within particular intervention areas, such as cost per quit in tobacco control and cost per additional helmet user in preventing head injuries.
The accompanying effectiveness review 2 estimated the proportion of product use within populations based on pooled intervention effects reported across different products. Similar pooling of estimates of costs and benefits for the economic review would not be sensible because the magnitudes of costs and benefits associated with the products, such as condoms and recreational helmets, differ. Pooling the economic effects for different types of distributed products might have been feasible had each study reported a standardized measure such as cost per QALY saved or cost-benefit ratio. Given the absence of such reporting, this economic review considered the evidence separately for each type of distributed product.
The literature search covered the period from January 1980 through December 2009. Sources of literature searches included those for the effectiveness review 2 and additional specialized databases of economic literature at the Center for Review and Dissemination at the University of York, JSTOR, and EconLit. All reported monetary values are in 2009 U.S. dollars, where adjustment for inflation used the Consumer Price Index from the Bureau of Labor Statistics, 4 and adjustments for values denominated in foreign currencies used purchasing power parities 5 from the World Bank. Data were analyzed in 2011.
Three research questions were posed for this review: (1) What is the cost of intervention including the costs of the media component and the product distribution component? (2) Are there any economic benefits through the intervention's effects on healthcare cost or productivity? and (3) How does cost compare to benefit, and is the intervention cost-beneficial or cost-effective?
Organization of Review Findings
Each study was reviewed for how well it answered questions about cost and benefit components and overall economic value. Results from included studies and discussions are grouped by type of distributed product and health outcome or health risk addressed by the intervention. Conclusions for groups of studies and overall conclusions are drawn about economic value and evidence gaps.
Search Results
The literature search produced a list of 15,491 references. Initial screening identified 59 candidate studies, and subsequent full-text review resulted in 15 unique studies (reported in 16 papers) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] with economic information, which were included in this review ( Figure 1 ).
Evidence Synthesis
Only two 12, 13 of the 15 included studies performed complete evaluations of economic costs and benefits of health communication campaigns with product distribution. Intervention cost was incomplete in most studies, which did not account for the cost of both media and product distribution. Four studies 9, 11, 14, 18, 19 provided the grant amount with little other information. More than three quarters of the studies in this review that provided information about the source of funding were publicly financed. The number of studies for each product in the effectiveness 2 and economic reviews is shown in Table 1 . Six studies 8, [10] [11] [12] [13] 16 included in the economic review were not in the effectiveness review. Two 8, 11 were secondary studies where the primary study was included in the effectiveness review, two 12, 13 were studies with modeled outcomes, and the remaining two studies 10, 16 reported intervention cost for various jurisdictions where the interventions were implemented. Table 2 provides a detailed description of all studies categorized by product type.
Interventions to Promote Booster Seats and Child Car Seats for Injury Prevention
The per capita cost of interventions to increase the use of booster seats could not be estimated because the one included study 19 provided only the total funded amount and did not provide an accurate estimate of the study population ( Table 2 ). The intervention was effective only in one of two targeted communities. In the other, the intervention was not cost-effective because the intervention cost was positive, but there was no effect on health outcome.
Interventions to Promote Pedometers to Increase Physical Activity
The study (reported in two papers) 9, 11 that evaluated the promotion of physical activity with distribution of pedometers found the cost of intervention to be $13.27 per adult resident. This intervention was not costeffective, as there was no change in self-reported physical activity following the intervention.
Condoms and Prevention of Sexually Transmitted Infections
Four studies 6, 13, 14, 16 evaluated campaigns with condom distribution to prevent sexually transmitted infections and pregnancies (Table 2) . Estimated per capita intervention cost varied widely, from $42 among adolescents in a large urban population 14 to $676 among young gay men (the Mpowerment program) in a small city. 13 A survey 16 of community-based organizations (CBOs) between 2002 and 2005 reported that the median annual budget for the Mpowerment program was about $80,370; per capita cost could not be calculated because sizes of target populations were not specified.
The evaluation 13 of the Mpowerment program was one of the few studies that provided complete accounting for intervention cost and also modeled the economic benefits based on averted medical care cost for HIV. The study assumed the percentage reduction in risk behavior measured by unprotected anal intercourse translated to an equal percentage reduction in HIV incidence.
The economic benefit of intervention was estimated as the averted cost of health care from prevented HIV infections, based on estimates from the literature. The cost of intervention was drawn from actual program costs and included the key components of promotion and product distribution. All costs were discounted and On the other hand, another study 6 of an intervention among adolescents found no change in condom use at last intercourse. Although per capita cost of intervention could not be calculated from the $276,617 program cost because the size of study population was not specified, the intervention was ineffective and hence could not have been cost-effective.
Given the paucity of studies that provided a complete economic analysis of both costs and benefits and the inconsistent results from cost-benefit and cost-effectiveness studies, a clear conclusion cannot be drawn about the economic value of the intervention.
Recreational Safety Helmets to Prevent Head Injury
Only two 18, 21 of five 8, 15, 17, 18, 21 included studies provided details on program costs, and no study provided sufficient information to compute cost-effectiveness ( Table 2 ). All studies evaluated promotion of bicycle helmets except one, 15 which was for ski helmets. Three 8,15,17 studies provided economic information only for the free or discounted helmet component of the intervention.
These partial estimates are presented here to emphasize that such interventions can be costly when implemented population-wide. One study 8 of bicycle helmet promotion among elementary school children reported an increase in sales from 1,500 units to more than 22,000 over a 2-year period, during which participating retailers offered the helmets for an average of $40 when the undiscounted prices in the area averaged $95.
Another helmet promotion 17 Two studies reported what may be a reasonably accurate estimate for intervention cost. A 5-month bicycle helmet promotion among 3,100 students from six middle and junior high schools and their parents was fully financed by a $358,355 grant. 18 The study found a 15.5 percentage point increase in helmet ownership and some increase in parent-reported helmet use. Based on the grant amount, the per capita cost was about $116 for this 5-month intervention.
The other study 21 evaluated a helmet promotion campaign implemented in Victoria, Australia, that offered purchase rebates. Partial program cost was provided as $294,286 for TV and radio campaigns and $745,200 for rebates over the approximate 1-year duration of the intervention (the rebate was calculated as an approximate value by the present reviewers). The study noted a substantial increase in helmet use among school children in the Melbourne metro area, as well as a 20% reduction in the incidence of bicycle-related head injury involving motor vehicle crashes in Victoria, when comparing injury data from 1982-1983 and 1984.
Nicotine Replacement Therapy and Tobacco Cessation
Four studies 7, 10, 12, 20 evaluated interventions promoting tobacco cessation through quitlines with distribution of NRTs ( Table 2) . Only one study 12 modeled life-years saved based on observed quits, indicating a cost per life-year saved that likely meets the standard threshold for costeffectiveness. Free or reduced-cost distribution of NRTs was consistently shown to increase calls to quitlines 7, 20 while also increasing quit rates 12, 20 among participants. The number of quits reported in the included studies was based on surveys of the population of callers to quitlines and does not account for quits that occurred within the larger population in response to the media component of the intervention. Similar to interventions for recreational helmets, reduced price and greater availability appear to increase use but also constitute a substantial cost of the intervention.
Results from two statewide studies 12, 20 suggest that incremental effectiveness in terms of call volume to quitlines is not sacrificed by relying on cheaper mass media such as earned versus paid media, and radio or print versus TV. However, the effect of the intervention is likely to diminish over time, and the use of paid mass media may be necessary to sustain the population-level change in behavior.
The first study 20 did not report the cost of product purchase and distribution, and the present reviewers assumed that the difference in media expenditures between the periods (about $1.44 million) went substantially to purchase NRTs. Daily call volume to quitlines increased from 78 to 188, and self-reported 7-day abstinence at 6-month follow-up increased from 10.3% to 14.9%. The second study 12 evaluated a change in intervention strategy that reduced TV and radio coverage cost from $1.58 million to $0.48 million and increased the outlay for free NRT plus counseling from $0.67 million to $2.08 million. The monthly average calls to quitlines increased from 536 in the pre-NRT period to 1,137 in the free NRT period, a difference of 7,212 per year, and quit rates increased from 8.2% to 15.7%.
Four variants of campaigns that promoted quitlines along with free NRT distribution operated in New York City (NYC) and three other regions of New York State during [2003] [2004] . 10 The campaign in NYC was longer in duration and offered a more generous 6-week supply of NRT patches to callers. Intervention cost ranged from $33 to $48 for three regions to $87 for NYC, and cost per quit ranged from $312 to $396, with the higher estimate associated with NYC and one other region. A 6-month follow-up evaluation 22 of the NYC program reported $3.28 million in program cost, with the NRT product contributing $2.93 million. At 12-month follow-up, 23 the cost per quit was $491.
Another study 7 of the New York quitline programs evaluated an intervention with three arms: a 4-week media campaign promoting the quitline plus free 2-week supply of NRT; a newspaper advertisement to call the quitline for a cessation guide; and a newspaper ad to call the quitline for the guide and a free cigarette look-alike containing no nicotine. Calls to the quitlines increased for all three arms, with the incremental cost per additional call at $12.54 for the first intervention, $93.48 for the cigarette look-alike arm, and $272.46 for the arm without the free product. The authors concluded that the free NRT program was preferable to the newspaper advertisement alone.
The one NRT study 12 that modeled long-term outcomes estimated cost per life-year saved at $98, which varied between $25 and $402 in sensitivity analysis. These estimates are below the conservative threshold for cost-effectiveness of $50,000 per QALY saved. Cost of intervention for this study was derived as the difference in observed cost of promotion and product distribution in the post-and pre-intervention periods.
Quit rates based on intent to treat were estimated from a survey of registered callers to the quitline, and quits were translated to life-years saved based on age-specific life expectancy for smokers and quitters derived from the literature. A discount rate of 3% was applied to life-years saved, and sensitivity analysis was performed based on upper and lower CI estimates for intervention cost and quit rates. Likely savings from healthcare cost averted were not included in this model, which could have improved the cost-effectiveness ratio.
Conclusions
The studies included in this review do not provide evidence to reach a conclusion about the economic merit of health communication campaigns that use mass media combined with product distribution. Some evidence suggests that this intervention strategy might be cost-effective in promoting condom use among high-risk populations and in promoting tobacco cessation with NRT products. However, the small body of evidence also includes studies of three instances of interventions with positive cost but no positive effect on health outcomes: child car booster seats to reduce injuries, pedometers to increase physical activity, and increasing condom use. These instances of the intervention were not cost-effective.
The scarcity of good quality estimates across three categories of information-cost of intervention, cost consequences for healthcare and worksite productivity, and life-years or QALYs saved-made determination of the intervention's economic merits difficult. Program costs reported in many studies were often incomplete; in-kind and voluntary contributions were not valued, or the product and distribution cost of this multicomponent intervention simply ignored. Cost consequences for healthcare and intervention effects on worksite productivity were rarely recorded or modeled.
Finally, the effects reported were often based on proximal outcomes specific to the intervention, such as incremental quits among smokers or reduction in unprotected sex. The determination of economic value of the intervention would require modeling these effects to monetary values for a cost-benefit assessment or to QALYs for a cost-effectiveness assessment.
Regarding study populations, although it is difficult to ascertain information on the treated population for mass media interventions, having at least an estimate of the population of interest is useful. This information, missing from some included studies, is needed to convert program costs to a per capita basis, so that similar interventions implemented in different populations can be compared.
A Key findings of the review were lack of documentation, rigor, and transparency for costs included or excluded; failure to value resources at opportunity cost; omission of capital and overhead costs; retrospective data collection; diversity of outcomes ranging from process outcomes to intermediate outcomes, particular to the health intervention and the rare use of standardized disabilityadjusted life-year or QALY; and design elements that prevented estimation of incremental cost-effectiveness due to intervention.
However, it may be noted that the last two observations are not unexpected for mass media interventions, given the acknowledged problems in designing controlled experiments when exposure to treatment is population-wide. The present review came to very similar findings and conclusions for the focused area of mass media campaigns that include health-related product distribution.
Providing a health-related product at a discount or no charge increases use and associated positive health behavior. Increased product acquisition may be due to removing non-price-related barriers to access, convenience of the distribution network, or price lowering. The importance of price is likely to be greatest where the product constitutes a large part of a population's income; a program that distributes such a product at a discount or no charge can expect a substantial outlay for the product component of this multicomponent intervention.
Yet, it may also require substantial funds to finance the distribution infrastructure for even a relatively inexpensive product, such as condoms. Reduced price or no-charge promotions for a relatively expensive product, such as recreational helmets, increases demand, and private sector or government funds must consistently be available to underwrite such costs. Many interventions were publicly funded trials or programs, and the failure to properly evaluate their economic cost and benefit is a serious gap in the science and practice of public health.
